Kansas House Bill HB2549

Kansas 2025-2026 Regular Session

• Introduced: 1/27/26
• Refer: 1/27/26

Caption

Mandating insurance coverage of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS).

Summary

HB 2549 would require most Kansas health insurance policies and health benefit plans delivered, issued, amended, or renewed on or after January 1, 2027, to cover the diagnosis and prescribed treatment of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). The bill defines both conditions and applies the mandate broadly to individual and group health insurance policies, medical service plans, hospital and medical service corporation contracts, fraternal benefit societies, and health maintenance organizations that provide accident and health coverage. The bill also updates the Kansas state employees health care program to include PANS and PANDAS coverage for the 2027 plan year and requires a report on utilization, costs, and program impact. That report is intended to inform whether the Legislature should continue or extend the mandate to the broader commercial insurance market. The bill amends existing insurance statutes to incorporate the new coverage requirement and repeals the prior versions of the affected sections.

Impact

HB 2549 would expand Kansas insurance law by creating a new mandated-benefit requirement for PANS and PANDAS diagnosis and treatment. It would affect private insurers, nonprofit medical and hospital service corporations, HMOs, and the state employee health plan, while tying the mandate to existing insurance code provisions and reporting requirements. The bill would also shift the effective date for broader market applicability to January 1, 2027, and would require legislative review based on state employee plan data before or alongside broader implementation.

Sentiment

Based on the bill text and available context, the overall sentiment appears supportive of adding coverage for these pediatric conditions, with the measure introduced by the House Committee on Health and Human Services and requested by a representative. The structure of the bill suggests an effort to build a factual record through the state employee health plan before fully extending the mandate statewide, indicating a cautious but affirmative approach. No committee transcript or vote record is available here to show opposition or formal debate.

Contention

The main point of contention is likely the cost and utilization impact of mandating coverage for relatively specialized pediatric diagnoses. The bill itself anticipates this concern by requiring a report on the state employee health plan’s experience, including utilization data, costs, and a recommendation on whether the coverage should continue. Another likely issue is whether the Legislature should impose the mandate immediately on all commercial plans or wait for more evidence from the state plan pilot period. Supporters would focus on access to diagnosis and treatment for affected children, while skeptics would likely question medical necessity, premium impact, and the sufficiency of the evidence base.